this is from the Oxford trial, some volunteers were asked to take paracetamol BEFORE and AFTER the vaccine and there was no difference in the effectiveness of the vaccine.
*UK trial
The randomised, controlled, single-blind trial of the Oxford vaccine ran between 23 April and 21 May 2020 and involveed 1,077 healthy adults aged 18–55 years with no history of COVID-19.
Participants received either the experimental COVID-19 vaccine or a licensed meningococcal conjugate vaccine (MenACWY); 113 participants were also asked to take paracetamol before and for 24 hours after their vaccination to lessen adverse reactions.
Ten participants assigned to a non-randomised, unblinded prime-boost group received a two-dose schedule of the COVID-19 vaccine, with the booster vaccine administered 28 days after the first dose.
The COVID-19 vaccine was found to have an acceptable safety profile and there were no serious adverse events.
Local and systemic reactions were more common in the COVID-19 group, although many were reduced by use of prophylactic paracetamol, including pain, feeling feverish, chills, muscle ache, headache, and malaise.
Fatigue and headache were the most commonly reported reactions: fatigue was reported by 70% of participants given the COVID-19 vaccine without paracetamol (71% of those with paracetamol), versus 48% of those given the MenACWY vaccine without paracetamol; headache was reported by 68% of the COVID-19 group without paracetamol (61% with paracetamol), versus 41% of participants in the MenACWY group without paracetamol.
Immune response
T-cell response to the SARS-CoV-2 spike protein peaked at day 14 and declined slightly by day 56; the antibody response peaked by day 28 and remained high at day 56. Antibody levels were boosted in people who received a second dose.
Neutralising antibody responses against SARS-CoV-2 were detected in more than 90% of participants (32/35) at 28 days after a single dose, and in 100% of the participants who received a booster dose.
Taking paracetamol did not affect the immunogenicity of the COVID-19 vaccine.
The authors note that a small number of participants had detectable neutralising antibodies and T-cell responses against SARS-CoV-2 spike protein before vaccination, likely to be due to past asymptomatic infection as individuals with recent COVID-19-like symptoms or a history of positive PCR test for SARS-CoV-2 were excluded from the study.
The trial participants will continue to be monitored for at least a year to further characterise the vaccine’s safety and immunogenicity.*
I think that I will put my faith in the scientists